(-0.11%) 5 463.51 points
(-0.32%) 38 987 points
(0.23%) 17 758 points
(0.40%) $81.15
(-3.48%) $2.66
(-0.94%) $2 309.00
(-0.41%) $28.75
(1.46%) $1 000.80
(0.28%) $0.936
(0.78%) $10.69
(0.41%) $0.791
(-0.25%) $87.28
Live Chart Being Loaded With Signals
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich\'s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations...
Stats | |
---|---|
本日の出来高 | 13 334 |
平均出来高 | 145 361 |
時価総額 | 536.02M |
EPS | $-0.770 ( Q1 | 2024-03-31 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0420 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-07 | Omega Fund Vi, L.p. | Buy | 454 545 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Buy | 287 213 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Buy | 1 415 865 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Sell | 2 615 533 | Series B convertible preferred stock |
2023-11-07 | Omega Fund Vi, L.p. | Sell | 14 999 999 | Series A convertible preferred stock |
INSIDER POWER |
---|
-79.48 |
Last 16 transactions |
Buy: 4 724 723 | Sell: 41 348 236 |
ボリューム 相関
Lexeo Therapeutics, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Lexeo Therapeutics, Inc. 相関 - 通貨/商品
Lexeo Therapeutics, Inc. 財務諸表
Annual | 2022 |
収益: | $654 000 |
総利益: | $654 000 (100.00 %) |
EPS: | $-2.40 |
FY | 2022 |
収益: | $654 000 |
総利益: | $654 000 (100.00 %) |
EPS: | $-2.40 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich\'s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。